Form 424B5 Inmune Bio, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
BTIG Downgrades INmune Bio Inc. (INMB) to Neutral
June 30, 2025 4:37 PM EDTBTIG analyst Thomas Shrader downgraded INmune Bio Inc. (NASDAQ: INMB) from Buy to Neutral.
The analyst comments "A solid MAYBE but with no clear way forward and management talking about moving to other programs - so NEUTRAL makes sense. The size of the AD opportunity hasn't changed, so the current stock price (about $2 all day) equates to a probability of success in AD of 0% with all revenues coming from MDD. Our two biggest worries going into this readout (preview HERE) were: 1) the modest enrichment in the MINDFul trial population, based on one (of four)... More
